Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Tabrecta Generic Name & Formulations
Legal Class
Rx
General Description
Capmatinib 150mg, 200mg; tabs.
Pharmacological Class
Kinase inhibitor.
How Supplied
Tabs—56
Manufacturer
Generic Availability
NO
Tabrecta Indications
Indications
In adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.
Tabrecta Dosage and Administration
Adult
Confirm presence of a mutation that leads to MET exon 14 skipping in tumor specimens. Swallow whole. 400mg twice daily. Dose modifications for adverse reactions: see full labeling.
Children
Not established.
Tabrecta Contraindications
Not Applicable
Tabrecta Boxed Warnings
Not Applicable
Tabrecta Warnings/Precautions
Warnings/Precautions
Monitor for pulmonary symptoms indicative of ILD/pneumonitis; withhold immediately if suspected and permanently discontinue if no other causes are identified. Monitor LFTs prior to initiation, every 2 weeks during 1st 3 months, then once monthly or as clinically indicated; test more frequently if increased AST, ALT or bilirubin develops. Monitor amylase and lipase at baseline and regularly during treatment. Potential risk of photosensitivity. Advise patients to limit direct UV exposure. Severe renal impairment (CrCl 15–29mL/min). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).
Tabrecta Pharmacokinetics
See Literature
Tabrecta Interactions
Interactions
Potentiated by strong CYP3A inhibitors; monitor closely. Potentiates CYP1A2, P-gp, or BCRP substrates; if unavoidable, reduce substrate dosage. May potentiate MATE1 or MATE2K substrates; if unavoidable, reduce substrate dosage. Antagonized by strong or possibly moderate CYP3A inducers; avoid.
Tabrecta Adverse Reactions
Adverse Reactions
Peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite, constipation, diarrhea, cough; lab abnormalities, ILD/pneumonitis, hepatotoxicity, pancreatic toxicity.
Tabrecta Clinical Trials
See Literature
Tabrecta Note
Not Applicable
Tabrecta Patient Counseling
See Literature
Images
